A Phase 1b Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer.

Trial Profile

A Phase 1b Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Demcizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 15 Dec 2011 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 15 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Oct 2010 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top